Determination of free levels of cinitipride in human plasma by liquid chromatography-tandem mass spectrometry

E-Journal of Chemistry

Volumn 5, Issue 3, 2008, Pages 453-460

  Roy, Shikha M N ^a   Yetal, Santosh M ^a   Chavan, Sangita V ^a   Pradhan, Varad R ^a   Joshi, Santosh S ^a  

^a GN Khalsa College   (India)

Author keywords

Cinitapride; Human plasma and LC MS MS

Indexed keywords

EID: 52649127373     PISSN: None     EISSN: 09734945     Source Type: Journal    
DOI: 10.1155/2008/242986     Document Type: Article

References (14)

1. Article: An improved process for the preparation of Cinitapride Hydrogen Tartarate Application 341/MUM/2004 published, 2007-03-02, filed, 2004-03-19
2. Gonzalez M I, Gonzalez P C and Blanco Lopez M A, Analytica Chimica Acta, 1998, 368(1), 175-181.
3. Alarcon de la Lastra C, La Casa C, Martin M J and Motilva V, Inflammation Research, 1998, 47(3),131-136.
4. Alberti J, Alvarez M, Navarro J and Salva M, Metabolismo in vitro de cinitaprida en presencia de microsomas hepáticos humanos. Identificación del citocromo P450 responsable del etabolismo de cinitapride. Data on File, Almirall Prodesfarma S A, 2000.
5. Crumb W J, Herg blocking profile of SD-33 (cinitapride). Data on File, Almirall Prodesfarma, S A, 2000.
6. De Graeve J, Identification by mass spectrometry of the chemical structures of in vivo human metabolites of cinitapride - Evaluation of their plasmatic and urinary elimination profiles. Data on File, Almirall Prodesfarma, 2001.
7. Fernandez A G and Roberts D J, Drugs Fut. 1991, 16 885-92.
8. Massingham R, Bou J and Roberts D J, J. Auton Pharmacol, 1985, 5, 41- 53.
9. Ames.Tonini M, De Ponti F, Di Nucci A and Crema F, Aliment Pharmacol Ther, 1999, 13, 1585-1591.
10. Totah RA and Rettie A E, Clin Pharmacol Ther. 2005, 77, 341-352.
11. U. S. Food and Drug Administration. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence, January 2001.
12. Department of Health Services, Food and Drug Administration.U.S., January 19, 2001, 66(13),5515-5517.
13. Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services. FDA. CDER. CVM. May 2001.
14. Marta Robert, Miquel Salva, Rosa Seggara, Marco Pavesi, Ramon Esdri, David Roberts and Georg Golor, Drug metabolism and disposition, Fast forward, April-2007.